US Patent No: 6,340,701

Number of patents in Portfolio can not be more than 2000

Cytotoxic agents comprising taxanes and their therapeutic use

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IMMUNOGEN, INC.WALTHAM, MA89

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blattler, Walter A Brookline, MA 30 570
Chari, Ravi V J Newton, MA 66 387

Cited Art

Patent Info (Count) # Cites Year
 
IMMUNOGEN, INC. (2)
5,416,064 Cytotoxic agents comprising maytansinoids and their therapeutic use 69 1992
5,475,092 Cell binding agent conjugates of analogues and derivatives of CC-1065 54 1994
 
ENZON, INC. (1)
5,824,701 Taxane-based prodrugs 50 1997
 
INDENA SPA GRUPPO INVERNI DELLA BEFFA (1)
5,475,011 Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment 46 1993
 
LIU, JIAN (1)
6,175,023 Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III 19 2000
 
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (1)
5,811,452 Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof 48 1997

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
IMMUNOGEN, INC. (20)
7,390,898 Cytotoxic agents containing novel potent taxanes and their therapeutic use 0 2003
7,202,346 Antibodies to non-shed Muc1 and Muc16, and uses thereof 1 2003
7,008,942 Cytotoxic agents comprising taxanes and their therapeutic use 0 2003
7,374,762 Drug conjugate composition 2 2004
7,495,114 Cytotoxic agents containing novel potent taxanes and their therapeutic use 0 2004
7,414,073 Cytotoxic agents containing novel potent taxanes and their therapeutic use 0 2004
7,217,819 Cytotoxic agents comprising taxanes and their therapeutic use 0 2005
7,834,155 CA6 antigen-specific cytotoxic conjugate and methods of using the same 0 2005
7,528,130 Cytotoxic agents comprising taxanes and their therapeutic use 0 2006
7,276,499 Cytotoxic agents comprising taxanes and their therapeutic use 0 2006
7,601,354 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents 0 2006
7,811,572 Process for preparing purified drug conjugates 0 2006
7,514,080 Drug conjugate composition 3 2006
7,501,120 Drug conjugate composition 2 2006
7,494,649 Drug conjugate composition 2 2006
7,550,609 Cytotoxic agents comprising taxanes and their therapeutic use 0 2007
7,476,669 Cytotoxic agents comprising taxanes and their therapeutic use 0 2007
7,585,857 Cytotoxic agents comprising taxanes and their therapeutic use 0 2007
8,012,485 Drug conjugate composition 1 2009
8,383,122 Process for preparing purified drug conjugates 0 2010
 
BRISTOL-MYERS SQUIBB COMPANY (2)
6,906,040 Method for reducing toxicity of combined chemotherapies 0 2001
6,927,211 Method for reducing toxicity of combined chemotherapies 0 2003
 
CORNELL RESEARCH FOUNDATION, INC. (2)
7,045,605 Modified antibodies to prostate-specific membrane antigen and uses thereof 5 2002
7,514,078 Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies 2 2003
 
SANOFI (2)
8,153,765 Anti-CD38 antibodies for the treatment of cancer 0 2007
8,404,678 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use 0 2010
 
AVENTIS PHARMA S.A. (1)
7,667,054 Cytotoxic agents comprising new taxanes 0 2005

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 22, 2013
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00